Hodgkin lymphoma (HL) Program in Pharmaceutical Benefits Scheme (PBS) 012-18042700

Background
Process
Resources
Training & Support

This document outlines details of PBS-subsidised brentuximab vedotin and pembrolizumab for patients with relapsed or refractory Hodgkin lymphoma (HL) and who have failed autologous stem cell transplant (ASCT) or are ASCT naïve.

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings. Contact Local Peer Support (LPS) if unsure of how to action an application.

Relapsed or refractory Hodgkin lymphoma (HL) quick reference

Restrictions	Authority level and section	PA assessment	Processing system	Prescriber type	Prescriber self-serve
Initial PB205	Written Electronic S100: brentuximab vedotin	No	OPA	Not specified	Yes
Continuing	Telephone Electronic S100: brentuximab vedotin	No	OPA	Not specified	Yes
Initial	Streamlined S100: pembrolizumab	No	OPA	Not specified	N/A
Continuing	Streamlined S100: pembrolizumab	No	OPA	Not specified	N/A

Operational Information

Hodgkin lymphoma (HL) Program in Pharmaceutical Benefits Scheme (PBS) 012-18042700

Relapsed or refractory Hodgkin lymphoma (HL) quick reference